Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG002 vs Chemotherapy in HER2-positive Urothelial Cancer
NCT05754853Phase 3Recruiting
- Sponsor
- Hangzhou Miracogen
- Start
- Apr 2023
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of MRG002 in urothelial carcinoma (UC), sponsored by Hangzhou Miracogen. Started Apr 2023; status: recruiting.
02
Drugs
MRG002
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05754853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05754853.